StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) bonds

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$187.96M
$70.00M due within a year
Net debt
-$131.89M
After $319.85M of cash
Implied interest rate
-8.65%
FY2025 interest ÷ average debt
Interest coverage
10.5×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Axsome Therapeutics's 10-Q for the period ended Jun 30, 2026

Axsome Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Revolving Facilities$90.00M
Tranche One$95.00M
Tranche One Sub Tranche Five$35.00M
Tranche One Sub Tranche Four$35.00M
Tranche One Sub Tranche One$95.00M
Tranche One Sub Tranche Three$30.00M
Tranche One Sub Tranche Two$55.00M
Tranche Three Sub Tranche One$15.00M
Tranche Three Sub Tranche Two$5.00M
Tranche Three Sub Tranches to One Tranche$75.00M
Tranche Two Sub Tranche One$35.00M
Tranche Two Sub Tranche Three$30.00M
Tranche Two Sub Tranche Two$35.00M
Tranche Two Sub Tranches To One Tranche$25.00M

See a number that looks wrong?